resveratrol 1 % gel: left side of face the patient will be given resveratrol 1 % gel once daily at night (Home use ).
TCA20%: left side of face the patient will be given resveratrol 1 % gel once daily at night (homThee use ).
Study summary
1. To evaluate the efficacy and safety of topical resveratrol 1 % gel in treatment of melasma.
2. To compare between the efficacy of topical resveratrol 1 %gel versrs chemical peeling with TCA 20% in melasma.
Eligibility
Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria:
* • Age: 18-50 years old.
* Pattern of melasma: Bilateral symmetrical facial melasma of any pattern.
* Fitzpatrick skin phototypes: Types III, IV and V.
Exclusion Criteria:
* Pregnancy and lactation.
* Patients taking oral contraceptive pills, hormonal replacement therapy or treatment for chronic illness at the time of the study or during the past 6 months.
* Coexistence of diseases associated with hyperpigmentation such as Addison disease.
* History of Scarring and keloid tendency
* Active skin infections as active HSV.
* Previous history of post- inflammatory hyperpigmentation.
Primary outcome measure(s)
The primary outcome is the change in hemi-Melasma Area and Severity Index (hemi-MASI) score from baseline to one month after the end of treatment (follow-up) — 3 months assessed by clinical evaluation and photographic documentation. Clinical efficacy will be categorized as:
Excellent response: \>75% decrease in hemi-MASI score
Very good response: 50-75% decrease in hemi-MASI score
Good response: 25-50% decrease in hemi-MASI score
Poor response: \<25% decrease in hemi-MASI score
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.